Potential biological targets for anti-Alzheimer drugs.
The stunning accumulation of data on the physiopathology of Alzheimer's disease is a real hinderance to pharmacologists who have to make decisions as to what molecules should be assessed first in man. Considering the cumbersomeness and cost of clinical trials in that field, a review of potential targets for drugs that are supposed to be active against the disease has become necessary, for a true definition of the rational justifications of trials to be envisaged.
Allain
H
H
Laboratoire de Pharmacologie, Faculté de Médecine, Hôpital Pontchaillou, Rennes, France.
Belliard
S
S
de Certaines
J
J
Bentué-Ferrer
D
D
Bureau
M
M
Lacroix
P
P
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D000641:Ammonia / Q000378:metabolism; D000682:Amyloid / Q000378:metabolism / Q000502:physiology; D016923:Cell Death / Q000187:drug effects; D006801:Humans; D018377:Neurotransmitter Agents / Q000378:metabolism / Q000502:physiology
D000682:Amyloid; D018377:Neurotransmitter Agents; D000641:Ammonia